-
-
-
Fosun Tourism Group Reported Record-High Revenue and Over 40% Profit Growth in the First Half of 2025
2025-08-28
(Shanghai, August 27, 2025) — Fosun International Limited (00656.HK) today announced the interim results of its subsidiary, Fosun Tourism Group (the “Group”), for the six months ended June 30, 2025. During the reporting period, Fosun Tourism Group delivered steady growth, with revenue reaching a historical high and adjusted net profit increasing by over 40% year-on-year.
-
-
-
-
Fosun International Announces 2025 Interim Results: Steady Growth in Core Businesses with Accelerated Innovation and Globalization
2025-08-27
(Hong Kong, Shanghai, 27 August 2025) Fosun International Limited (HKEX stock code: 00656, “Fosun International”), together with its subsidiaries (“Fosun” or the “Group”), today announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”).
-
-
-
-
Fosun Pharma Announces 2025 Interim Results: Enhancing Innovation Efficiency and Steadily Expanding Globally
2025-08-26
(August 26, 2025, Shanghai, China) — On August 26, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “the Group”; SSE: 600196, HKEX: 02196), a leading innovation-driven global healthcare company, announced its operating performance for the first half of 2025 (“the Reporting Period”).
-
-
-
-
Henlius Keeps Steady Growth in H1 2025: Overseas Product Profits Soar 200%+, Innovation Fuels Global Reach
2025-08-25
Shanghai, China, August 25, 2025 – Henlius (2696.HK) announced its 2025 interim results. In the first half of 2025, Henlius' revenue reached about RMB2.8195 billion, representing an increase of 2.7% YoY. The gross profit of RMB2.1992 billion, up by 10.5% YoY, with a net profit reached RMB390.1 million. Operating cash flow reached RMB770.9 million, with an increase of 206.8% YoY, maintaining a steady positive inflow.
-
-
-
-
Sisram Medical Reports First-Half 2025 Results: Injectables Surge as AI-Powered EBD Strengthens Segment Positioning
2025-08-21
HONG KONG, August 20, 2025 -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; referred to collectively with its subsidiaries as the "Group"), a global consumer wellness group, featuring a distinguished synergistic ecosystem of business building blocks and consumer-focused approaches including Energy-Based Devices (EBD), and Injectables, alongside other complementary offerings, today announced its unaudited consolidated interim results for the six months ended June 30, 2025 (the "Reporting Period").
-
-
-
-
Fosun International 2024 Annual Results Presentation: Aiming for RMB10 Billion in Future Industrial Operation Profit
2025-04-01
On 1 April 2025, Fosun International Limited (HKEX stock code: 00656, “Fosun International”), together with its subsidiaries (“Fosun” or the “Group”) held its 2024 annual results presentation in Shanghai. The results presentation was attended by Guo Guangchang, Chairman of Fosun International, Wang Qunbin, Co-Chairman of Fosun International, Chen Qiyu and Xu Xiaoliang, Co-CEOs of Fosun International, Gong Ping, CFO of Fosun International, and a number of institutional investors and analysts.
-
-
-
-
Fosun International Announces 2024 Annual Results: Total Revenue Reaches RMB192.14 Billion, Industrial Operation Profit Amounts to RMB4.9 Billion, Overall Operational Fundamentals Remain Stable
2025-03-30
(Hong Kong, Shanghai, 30 March 2025) Fosun International Limited (HKEX stock code: 00656, “Fosun International”), together with its subsidiaries (“Fosun” or the “Group”), today announced its annual results for the year ended 31 December 2024 (the “Reporting Period”).
-
-
-
-
Fosun International Successfully Refinanced USD 870 Million Offshore Syndicated Loan
2025-03-28
Fosun International (HKEX stock code: 00656, hereinafter referred to as "Fosun International", "Fosun", or the "Company") has successfully completed the refinancing of a USD 870 million equivalent syndicated loan due on March 28, 2025. Of this amount, USD 675 million equivalent was secured through a newly arranged syndicated loan. Consistent with the Company’s past practices, the new syndicated loan includes a greenshoe option, allowing additional banks to participate.
-
-
-
-
Fosun Pharma Announces 2024 Annual Results: Accelerates Globalization of Innovative Products with Operating Cash Flow Surging 31.13% YoY
2025-03-25
(March 25, 2025, Shanghai, China) On March 25, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”or “the Group”; Stock Code: 600196.SH, 02196.HK),a leading global pharmaceutical and healthcare company driven by innovation, announced its annual results for the year ended 31 December 2024 (“the Reporting Period”).
-